← All trials
NCT05615948
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 6, 2022
- Primary completion
- Jun 30, 2023
- Completion date
- Oct 31, 2023
- First posted
- Nov 14, 2022
- Last posted
- Dec 14, 2022
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Maimonides Medical CenterLead sponsor
- Maimonides Medical CenterOverall official - principal investigator
Drugs studied
Indications studied
- Analgesia
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Central Nervous System Depressants
- Depression
- Major Depressive Disorder
- Ketamine
- Peripheral Nervous System Agents
- Neurotransmitter Agents
- Sensory System Agents
- Analgesics, Non-Narcotic
- Physiological Effects of Drugs
- Depressive Disorder, Treatment-Resistant
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.